Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening
read more
Citations
Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
WM-DOVA maps for accurate polyp highlighting in colonoscopy: Validation vs. saliency maps from physicians
Long-term mortality after screening for colorectal cancer.
Epigenetics of colorectal cancer: biomarker and therapeutic potential.
Colorectal cancer population screening programs worldwide in 2016: An update.
References
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup.
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.
What is meant by intention to treat analysis? Survey of published randomised controlled trials
Use of Colonoscopy to Screen Asymptomatic Adults for Colorectal Cancer
Related Papers (5)
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.
Frequently Asked Questions (11)
Q2. What are the future works mentioned in the paper "Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening" ?
Org february 23, 2012706 where do the authors stand and what is the future ?
Q3. What are the two methods of colorectal cancer screening?
Colonoscopy and fecal immunochemical testing (FIT) are accepted strategies for colorectal-cancer screening in the average-risk population.
Q4. What is the common method of screening for colorectal cancer?
Stool tests for occult blood (guaiac testing and fecal immunochemical testing [FIT]) are predominantly used in Europe and Australia, whereas colonoscopy is the predominant screening method in the United States.
Q5. how many years of FIT screening would be considered a noninferior test?
The authors hypothesized that FIT screening every 2 years would be noninferior to one-time colonoscopy with respect to a reduction in mortality related to colorectal cancer among average-risk subjects.
Q6. How much is the rate of death associated with colonoscopy?
In a cohort of average-risk subjects, the use of screening colonoscopy was associated with a reduction in the incidence of colorectal cancer of 67% and a reduction in the rate of death of 65%.
Q7. What are the three main categories of tests for colorectal cancer?
Recommended strategies for colorectal-cancer screening fall into two broad categories: stool tests (occult blood and exfoliated DNA tests) and structural examinations (flexible sigmoidoscopy, colonoscopy, and computed tomographic colonography).
Q8. How many subjects were found to have colorectal cancer?
Colorectal cancer was found in 30 subjects (0.1%) in the colonoscopy group and 33 subjects (0.1%) in the FIT group (odds ratio, 0.99; 95% confidence interval [CI], 0.61 to 1.64; P = 0.99).
Q9. What is the accurate test for colorectal cancer?
Although data from randomized studies evaluating the effect of colonoscopy on the rate of death from colorectal cancer are lacking, the procedure is recommended as a first-line screening test on the basis of indirect data and observational studies.
Q10. What is the effective method for detecting colorectal cancer?
Population-based case–control studies have suggested that colonoscopy markedly reduces the risk of colorectal cancer7,8 and death.9
Q11. What is the name of the study?
All rights reserved.n engl j med 366;8 nejm.org february 23, 2012698Colorectal cancer is the third most common cancer worldwide and the second leading cause of cancer-related deaths.